Ashwagandha Root vs Leaf Extract: Why the Plant Part Matters

Ashwagandha Root vs Leaf is a distinction that gets overlooked on supplement labels, yet it shapes everything from withanolide content to the type of clinical evidence behind a product. If you are comparing ashwagandha supplements, knowing which plant part was used—and whether the extract was standardized—matters more than the milligram count on the front of the bottle.

What the Labels Don't Always Tell You

Withania somnifera is a small shrub native to India and North Africa. Manufacturers can extract bioactive compounds from the root, the leaf, or a blend of both. The root has been the traditional source in Ayurvedic preparations for centuries, while leaf extracts entered the market more recently, often marketed for higher withanolide concentrations.

Withanolides are the steroidal lactones responsible for most of ashwagandha's studied pharmacological effects. However, the root and leaf do not deliver identical withanolide profiles. Root extracts tend to be richer in withanolide A, whereas leaf extracts may contain higher levels of certain other withanolides and flavonoids. The clinical significance of these differences is still being explored, but the research base is not evenly distributed between the two plant parts.

The Evidence Base

When you look at the human randomized controlled trials that have shaped ashwagandha's reputation for stress, sleep, strength, and cognition, an overwhelming pattern emerges: the evidence is root-centric.

Chandrasekhar et al. (2012) conducted a prospective, randomized double-blind, placebo-controlled study using a high-concentration full-spectrum root extract in adults with chronic stress. The treatment group received 300 mg twice daily. After 60 days, serum cortisol reductions and improvements in stress-assessment scores were significantly greater than placebo. This trial helped establish the 600 mg daily dose benchmark still referenced today.

Langade et al. (2019) similarly used a root extract in a randomized, double-blind, placebo-controlled study of patients with insomnia and anxiety. Dosing was 300 mg twice daily. Sleep onset latency, sleep efficiency, and total sleep time improved in the active group versus placebo. Again, the extract was derived from root, not leaf.

Wankhede et al. (2015) examined muscle strength and recovery in healthy adults using a root extract at 300 mg twice daily for eight weeks. Significant increases in muscle strength on bench-press and leg-extension exercises, plus greater muscle size gains, were observed in the ashwagandha group. The study population was young, recreationally active men, and the intervention was root-based.

Choudhary et al. (2017) investigated memory and cognitive functions in adults with mild cognitive impairment using 300 mg of root extract twice daily. After eight weeks, improvements were seen in immediate and general memory, sustained attention, and executive function. The extract was a full-spectrum root preparation.

Pratte et al. (2014) published a systematic review of human trial results for ashwagandha as an alternative treatment for anxiety. The review noted that the majority of available human trials at the time used root or root-and-leaf extracts, but emphasized that the best-supported preparations were standardized root extracts. The authors called for more rigorous, larger-scale trials while acknowledging promising signals for stress and anxiety reduction.

<

Study	Plant Part	Design	Dose	Primary Outcome	Evidence Quality
Chandrasekhar et al. (2012)	Root	RCT, double-blind, placebo-controlled	300 mg × 2/day	Stress and cortisol reduction	Moderate
Langade et al. (2019)	Root	RCT, double-blind, placebo-controlled	300 mg × 2/day	Sleep quality and anxiety	Moderate
Wankhede et al. (2015)	Root	RCT, double-blind, placebo-controlled	300 mg × 2/day	Muscle strength and recovery	Moderate
Choudhary et al. (2017)	Root	RCT, double-blind, placebo-controlled	300 mg × 2/day	Memory and cognitive function	Moderate
Pratte et al. (2014)	Root / Root-Leaf	Systematic review	Varied	Anxiety outcomes across trials	Moderate (limited trial count)

Leaf-only extracts have far less published human trial data. In vitro and animal studies suggest leaf-derived compounds possess antioxidant and anti-inflammatory activity, but translating that to recommended human dosing is speculative. If a product relies on leaf extract, it is operating outside the best-characterized evidence base.

The Mechanism

Withanolides modulate the hypothalamic-pituitary-adrenal (HPA) axis, the body's central stress-response system. Chronic stress elevates cortisol, which, over time, impairs sleep, memory consolidation, and muscle recovery. Root-derived withanolides appear to blunt excess cortisol signaling and support GABA receptor activity, producing anxiolytic and calming effects without the sedation typical of pharmaceutical alternatives.

Some research also points to anti-inflammatory and antioxidant mechanisms. Withanolides can inhibit NF-κB signaling and reduce markers of oxidative stress. These effects may explain the muscle-recovery benefits observed in resistance-training studies, as exercise-induced muscle damage is partly driven by inflammatory cascades.

Whether leaf-derived withanolides produce identical HPA-axis modulation at comparable doses is not well established. The phytochemical matrix differs, and clinical pharmacokinetic data comparing root versus leaf in humans is essentially absent. Until head-to-head trials exist, assuming parity is unsupported.

Standardization Matters More Than Milligrams

A label claiming "500 mg ashwagandha" tells you little. Was it raw powder or an extract? If an extract, what percentage of withanolides? Was it standardized to a specific compound or simply a crude preparation?

The trials cited above used extracts standardized to a defined withanolide content, typically via a proprietary full-spectrum root extraction process. This consistency allows for reproducible dosing and more reliable outcomes. Raw root powder contains far lower withanolide density, meaning gram-scale doses of powder may deliver less active compound than a few hundred milligrams of a concentrated extract.

Leaf extracts sometimes advertise higher withanolide percentages, but without the same depth of human clinical validation. A higher number on a spec sheet does not automatically translate to superior efficacy if the specific withanolide profile and the human data backing it are thinner. For readers evaluating options, our breakdown of Best Ashwagandha Supplements 2026: KSM-66, Sensoril, and the Rest Ranked covers how to read standardization claims critically.

For those tracking their own dosing, Ashwagandha Dosage Guide: How Much KSM-66 Do You Actually Need? walks through the evidence-based ranges and why more is not always better.

Who Benefits Most

The strongest human evidence supports root-based ashwagandha for several specific populations and use cases:

Adults with chronic stress or elevated cortisol. Chandrasekhar et al. (2012) demonstrated meaningful cortisol reduction and improved stress scores in this group with 600 mg daily of root extract over two months.

Individuals with insomnia or anxiety-related sleep disturbance. Langade et al. (2019) showed improvements in sleep efficiency and onset latency using root extract, suggesting a role for non-pharmacological sleep support.

Recreational athletes seeking strength and recovery gains. Wankhede et al. (2015) found enhanced muscle strength and size in young men undergoing resistance training while supplementing with root extract.

Older adults with mild cognitive concerns. Choudhary et al. (2017) reported memory and attention benefits in adults with mild cognitive impairment using root extract over eight weeks.

These populations share one thing: their benefits are tied to root-extract trials. Leaf extract may appeal to those seeking antioxidant support, but the human data is not yet comparable. For a broader overview of the clinical landscape, KSM-66 Ashwagandha: All the Clinically Studied Benefits in One Place consolidates the research across these domains.

What the Evidence Doesn't Show

It is worth being explicit about the gaps. No published head-to-head RCT has directly compared root-only versus leaf-only extracts for stress, sleep, strength, or cognition in humans. The withanolide content of leaf extracts may differ quantitatively and qualitatively from root preparations, but clinical equivalence remains unproven.

Long-term safety data beyond a few months is limited. The trials above ran 8–12 weeks. While traditional use of root spans centuries, modern standardized extracts at higher concentrations have not been studied for multi-year use in controlled settings. Standard pregnancy and autoimmune cautions apply, and anyone on thyroid or sedative medications should consult a clinician before use.

Finally, not all root extracts are equivalent. Proprietary extraction methods vary in solvent type, withanolide standardization, and whether the final product preserves the full spectrum of root compounds or isolates a fraction. The studies cited used specific, well-characterized preparations. Generalizing their results to every root extract on the market requires caution.

Practical Takeaways

• Most published human RCTs on ashwagandha for stress, sleep, strength, and cognition used root extracts, not leaf extracts.
• Leaf extracts may contain different withanolide profiles and lack equivalent clinical validation in humans.
• Standardization matters more than raw milligram weight: look for defined withanolide content and extraction method.
• Evidence-based dosing from RCTs is typically 300 mg twice daily of a concentrated root extract.
• Effects on stress and cortisol appear within weeks, while strength and cognitive benefits may require 8+ weeks of consistent use.
• Products like Bio:sudo KSM-66 Reishi Restore use a root-based KSM-66 extract standardized to the withanolide profile backed by the bulk of human trials.

Bottom Line

If you are choosing an ashwagandha supplement for stress, sleep, strength, or cognitive support, the evidence base overwhelmingly favors root extracts—specifically standardized, concentrated root preparations used in controlled human trials. Leaf extracts may have theoretical advantages in other areas, but for the outcomes most people seek, root is the plant part with the data behind it. Until equivalent leaf-only RCTs are published, root-derived extracts remain the more evidence-grounded choice.

References

1. Chandrasekhar K, et al. "A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults." Indian Journal of Psychological Medicine. 2012;34(3):255–262. [Source]
2. Langade D, et al. "Efficacy and safety of ashwagandha (Withania somnifera) root extract in insomnia and anxiety." Medicine. 2019;98(37):e17186. [Source]
3. Wankhede S, et al. "Examining the effect of Withania somnifera supplementation on muscle strength and recovery." Journal of the International Society of Sports Nutrition. 2015;12:43. [Source]
4. Choudhary D, et al. "Efficacy and safety of ashwagandha (Withania somnifera) root extract in improving memory and cognitive functions." Journal of Dietary Supplements. 2017;14(6):599–612. [Source]
5. Pratte MA, et al. "An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha." Journal of Alternative and Complementary Medicine. 2014;20(12):901–908. [Source]

---

---